By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Antineoplastics are drugs that fight cancer. Irinotecan is one of them. By interfering with the genetic material known as DNA, which is required for their growth and reproduction, it kills cancer cells.
Typically, Irinotecan is used in conjunction with other treatments.After receiving treatment with 5-fluouracil, it may also be used by itself to treat colon or rectal cancer that has spread to other parts of the body.
Every mL of clean, clear, light yellow, fluid arrangement contains 20 mg irinotecan hydrochloride (as the trihydrate).Ingredients that aren’t medicine:For injection, 45 mg of sorbitol, 0.9 mg of lactic acid, and water.
To bring the pH level to between 3.0 and 3.8, sodium hydroxide and/or hydrochloric acid can be used.
The recommended dose and schedule for irinotecan varies depending on the stage of therapy, the stage of cancer, the person’s response to therapy, and their body size.
Irinotecan is given in cycles that incorporate rest periods between medicines.
Through a site on the skin that has been specifically prepared, it is injected into a vein.
Typically, an infusion of approximately 90 minutes is used to administer the appropriate dose of irinotecan.
Until it is determined that treatment has been completed, this cycle is repeated.When handling this medication, extreme caution is required.
In a hospital or other similar setting with access to sterile equipment for preparation, irrinotecan is always administered under the direction of a physician.
The Global Irinotecan HCL injection market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The introduction of irinotecan hydrochloride injection in the United States was recently announced by Hospira, Inc., the global leader in generic injectable pharmaceuticals.
Irinotecan hydrochloride injection is used to treat patients with colon or rectal cancer whose disease has recurred or progressed after treatment with other treatments.
It is a generic version of Pfizer’s Camptosar. The range of irinotecan products offered by Hospira goes beyond the innovator’s own formulations.
Hospira is marketing a 500 mg single-dose vial of the medication in addition to the 40 mg and 100 mg single-dose vials for additional convenience when preparing and delivering larger doses.
The organization bundles irinotecan in its restrictive Onco-Tain vials for safe taking care of.
With more than 190 generic injectable products available in more than 900 dosages and formulations, Hospira has the world’s largest generic injectable product portfolio.
Cardiovascular, anesthesia, anti-infectives, oncology, analgesics, emergency, and other therapeutic areas are all product areas.
Over the coming years, a number of proprietary non-biologic drugs will see their patents expire around the world. Many of these compounds are in Hospira’s extensive product pipeline.
Hospira uses unit-of-use bar codes on the labels of all of its injectable products to help reduce medication errors.
Irinotecan is already sold by Hospira in several European nations, Australia, and Canada.
